This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA approves ibrutinib in ‘practice-changing breakthrough,’ Omega-3 fatty acids beneficial for obese patients with breast cancer
Click Here to Manage Email Alerts
Among the top stories in hematology/oncology is a possible practice-changing breakthrough with the FDA approval of ibrutinib for adults with chronic graft-versus-host disease. Women with breast cancer and a high BMI experienced improved aromatase inhibitor-associated arthralgia symptoms after treatment with omega-3 fatty acids. Other top stories include an editorial examining the concept of genome-driven oncology, a phase 2 trial showed that intralesional agent SD-101 plus pembrolizumab induced a high response rate with a tolerable safety profile, and 70 NCI-designated cancer centers in the U.S. issued a joint statement calling for increased gender-neutral HPV vaccination and evidence-based screening.
GVHD management improves, but questions remain about risk stratification, prophylaxis
The FDA approval of ibrutinib for adults with chronic graft-versus-host disease may herald a practice-changing breakthrough in the management of this posttransplant complication. Read More.
Omega-3 fatty acid use improves symptoms among obese patients with breast cancer
Aromatase inhibitor-associated arthralgia symptoms improved among women with breast cancer and a high BMI after treatment with omega-3 fatty acids, according to findings presented at ASCO Annual Meeting. Read More.
Delivering on the promise of precision oncology
The concept of genome-driven oncology became a reality almost 20 years ago with the introduction of imatinib, targeted to the ABL kinase. Read More.
Combination therapy with SD-101, pembrolizumab shows promise for metastatic melanoma
Intralesional agent SD-101 plus pembrolizumab induced a high response rate with a tolerable safety profile among a small cohort of patients with metastatic melanoma, according to results of a phase 1b/phase 2 trial presented at ASCO Annual Meeting. Read More.
Cancer centers join forces to eliminate HPV-related cancers
The nation’s 70 NCI-designated cancer centers issued a joint statement today calling for increased gender-neutral HPV vaccination and evidence-based screening in hopes of eliminating cancers caused by the virus. Read More.